- Performance of the Medical Research Council (MRC) and the Leukemia Research Foundation (LRF) score in predicting survival benefit with hypomethylating agent use in patients with relapsed or refractory acute myeloid leukemia. Leukemia and Lymphoma. 2018 Academic Article GET IT
Allogeneic Hematopoietic Stem Cell Transplantation Following the Use of Hypomethylating Agents among Patients with Relapsed or Refractory AML: Findings from an International Retrospective Study.
Biology of Blood and Marrow Transplantation.
Times cited: 2
Guadecitabine (SGI-110) in treatment-naive patients with acute myeloid leukaemia: Phase 2 results from a multicentre, randomised, phase 1/2 trial.
The Lancet Oncology.
Times cited: 54
Patterns of Venous Thromboembolism Prophylaxis during Treatment of Acute Leukemia: Results of a North American Web-Based Survey.
Clinical Lymphoma, Myeloma and Leukemia.
Times cited: 9